Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
FIGS Q3 2025 Earnings Call - Strong Execution Drives Highest Revenue Growth in Two Years Amid Tariff Headwinds
FIGS reported an 8% year-over-year revenue increase in Q3 2025, marking its strongest growth in two years. Leadership highlighted solid demand across core categories and geographies, driven by optimiz...
- Q3 net revenues rose 8% YoY to $151.7 million, the highest growth rate in two years.
- Gross margin expanded 280 bps to 69.9%, achieving best quarterly performance since early 2023.
- Adjusted EBITDA margin surged 900 bps to 12.4%, reflecting operational leverage and tariff mitigation.
- +17 more takeaways
MP Materials Q3 2025 Earnings Call - Accelerated Vertical Integration and Profitable Growth Fueled by DoD and Apple Partnerships
MP Materials delivered a landmark Q3 2025, marked by record NdPr oxide production and a significant ramp-up in magnetics manufacturing capabilities. The company is on track to achieve a 60K metric ton...
- Record NdPr oxide production of 721 metric tons in Q3, a 21% sequential increase and 51% year-over-year growth, exceeding guidance.
- MP is advancing toward its upstream goal of 60,000 metric tons annual rare earth oxide output with consistent quarterly results over 13,000 metric tons REO.
- A new heavy rare earth separation circuit is under construction, expected to process 3,000 metric tons of feedstock, producing 200+ metric tons of dysprosium and terbium annually starting mid-2026.
- +17 more takeaways
Alpha Teknova Q3 2025 Earnings Call - Fifth Consecutive Quarter of Revenue Growth Driven by Lab Essentials
Alpha Teknova delivered its fifth consecutive quarter of year-over-year revenue growth in Q3 2025, reporting a 9% increase to $10.5 million, largely propelled by a 16% jump in Lab Essentials sales. Wh...
- Alpha Teknova achieved 9% year-over-year revenue growth in Q3 2025, marking the fifth straight quarter of gains.
- Lab Essentials product revenue increased 16%, driving the overall top-line growth.
- Clinical Solutions revenue decreased 13%, affected by lower average spend per customer despite a higher customer count.
- +15 more takeaways
Lionsgate Studios Corporation Q2 2026 Earnings Call - Record $1B Library Revenue and Tentpole-driven Fiscal 2027 Growth Outlook
Lionsgate Studios reported Q2 2026 revenues in line with expectations, highlighted by a record trailing 12-month library revenue surpassing $1 billion. The company is aggressively investing in tentpol...
- Trailing 12-month library revenue exceeded $1 billion for the first time, marking a record and underscoring Lionsgate's valuable intellectual property portfolio.
- Fiscal Q2 2026 revenue was $475 million with adjusted EBITDA of $14 million and an operating loss of $46 million; adjusted loss per share was $0.20.
- Lionsgate's film slate includes major tentpoles: 'Michael' releasing April 2027, 'The Hunger Games: Sunrise on the Reaping' November 2027, and two 'Resurrection' films starting March 2027.
- +17 more takeaways
PureCycle Technologies 3Q 2025 Earnings Call - Progress in scaling operations and initial shipments to major brands
PureCycle Technologies reported solid progress in the third quarter of 2025, with operational ramps at their Denver and Ironton facilities marking record production levels. The company is beginning to...
- PureCycle achieved one of its highest production quarters ever in Q3 2025, with September hitting a record 3.3 million pounds of recycled resin.
- The Denver facility added a second shift during Q3 and plans a third in Q4, targeting roughly $100 million in annual capacity.
- Ironton's compounding expansion is on track for mechanical completion in December and starts producing sellable pellets from CoProduct 2, reducing feedstock cost by ~20%.
- +12 more takeaways
Airbnb Q3 2025 Earnings Call - Strategic Expansion and AI Integration Fuel Record Profitability
Airbnb posted a robust Q3 2025 with revenues climbing 10% year-over-year, gross booking value up 14%, and adjusted EBITDA hitting a record $2.1 billion with a 50% margin. The company’s growth engines ...
- Q3 2025 revenue rose 10% YoY to $4.1 billion, gross booking value grew 14%, and adjusted EBITDA reached a quarterly record of $2.1 billion with a 50% margin.
- Nights and seats booked increased 9% YoY, driven by strong U.S. market demand and higher average daily rates (ADR).
- Airbnb made 65 major product improvements since May including Reserve Now, Pay Later launched in the U.S., improved mapping features, and more flexible cancellation policies.
- +9 more takeaways
Amprius Technologies Q3 2025 Earnings Call - Breaking Records with Silicon Anode Battery Expansion and Customer Growth
Amprius Technologies delivered a record-breaking third quarter in 2025 with $21.4 million revenue, marking a 42% sequential and 173% year-over-year increase. The company's second-generation CyCore sil...
- Q3 revenue hit $21.4 million, up 42% sequentially and 173% year-over-year, marking a record quarter.
- Amprius shipped batteries to 159 customers in Q3, including 80 new ones, expanding total customer base to 444.
- Second-generation CyCore batteries led growth with 4X shipment increase compared to prior year.
- +17 more takeaways
Grindr Q3 2025 Earnings Call - Strong Revenue Growth, New Pricing Tests, and AI-Driven Premium Tier on Horizon
Grindr's Q3 2025 results showcase robust momentum with 30% YoY revenue growth hitting $116 million and a record 47% adjusted EBITDA margin. The firm is raising its full-year EBITDA guidance to $191-$1...
- Q3 revenue grew 30% YoY to $116 million, with adjusted EBITDA up 37% to $55 million and margin at a record 47%.
- Grindr raised full-year 2025 adjusted EBITDA guidance to $191-$193 million, aiming for over 43% margin and reaffirming 26%+ revenue growth.
- The company completed successful subscription price increase tests with minimal impact on new subscriber conversion and retention.
- +9 more takeaways
Nektar Therapeutics Q3 2025 Earnings Call - REZPEG Poised to Redefine Autoimmune Dermatology with Promising Data and Extended Runway
Nektar Therapeutics spotlighted progress in its lead immunomodulatory candidate, REZPEG, as it advances toward pivotal trials in moderate to severe atopic dermatitis and alopecia areata. The company e...
- REZPEG advances toward Phase 3 for moderate to severe atopic dermatitis with supportive Phase 2b data showing statistically significant improvements in EASI scores and other clinical endpoints.
- Nektar’s REZPEG operates via novel T regulatory cell stimulation, a mechanism recently recognized by the Nobel Prize, underscoring its scientific validity and differentiation.
- Atopic dermatitis patients with comorbid asthma (approximately 25%) showed promising REZPEG responses in a pre-planned analysis, offering a clinical edge over existing IL-13 and OX-40 blockers.
- +11 more takeaways
Maravai LifeSciences Q3 2025 Earnings Call - Positioned for Positive EBITDA and Growth in 2026 Despite Q3 Revenue Challenges
Maravai LifeSciences reported Q3 2025 revenues of $41.6 million, with Biologics Safety Testing (BST) growing 7% to $16.3 million, while Nucleic Acid Products (NAP) declined 53% to $25.4 million, drive...
- Q3 2025 total revenue was $41.6 million, down from $69 million in Q3 2024, mainly due to a 53% decline in NAP segment.
- BST segment grew 7% year-over-year to $16.3 million, driven by strong demand in the U.S. and Europe and adoption of novel assays and services.
- NAP segment revenue declined 53%, affected by order timing in GMP consumables and absence of COVID GMP CleanCap sales, with expectations for strong Q4 rebound.
- +7 more takeaways